Shah Capital has ended its attempts to exert influence over vaccine developer Novavax, bringing more than years of activism ...

The immunology alliance follows a collaboration between the UK Biobank and the University of Exeter, supported by the Novo ...

Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight. From temperature monitoring devices and connected containers ...

Swiss biotech Nouscom has closed a €120 million ($135 million) fourth-round financing for a vaccine to protect people with a ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

A large-scale observational study has suggested that smartphones and watches may be able to spot mild cognitive impairment (MCI) during daily usage. The results of the Intuition Brain Health study – ...

Understanding the needs and behaviour of healthcare professionals is the number one priority for pharma as it interacts with the medical profession in 2024, marking a gradual shift away from a focus ...

After joining with Endo earlier this year, Mallinckrodt has completed its restructuring with the spinout of generic and sterile injectables unit Par Health, emerging from the process with a new name – ...

The European Commission has approved Johnson & Johnson's Ebola vaccine, developed by its Janssen pharmaceuticals unit and Bavarian Nordic. This is the first major regulatory approval of the vaccine ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new data – ...

The full data from AstraZeneca's phase 3 BaxHTN trial of baxdrostat has raised hope of an important new treatment option for people who struggle to control their blood pressure with current therapies.

Two senior executives formerly at mRNA specialist BioNTech have lifted the curtain on a new biotech called Bios Life that they call "an AI-native cancer surveillance company." Ex-BioNTech chief ...